Refine by
Medical And Development Officer Articles & Analysis
391 news found
MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized version of the highly validated liquid biopsy test developed by Memorial Sloan Kettering Cancer Center (MSK), a top cancer treatment and research institution. ...
“The capabilities that SOPHiA GENETICS provides, from assay development to clinical trial use, help enable this first-in-human precision medicine clinical ...
FOLR1 testing is recommended for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.1 “Expanding our offerings to include tests for specific, predictive biomarkers, like HER2, can help reveal a patient’s responsiveness to therapies that have the potential to positively impact their outcome,” said Ezra Cohen, MD, Chief Medical ...
ByTempus
Caresyntax, the leading vendor of enterprise-scale data-driven surgical intelligence solutions to make surgery safer and smarter, today announced its highlights and achievements of 2023, as the company has continued its strong growth journey. Dennis Kogan, co-founder, and CEO: “Caresyntax celebrated its 10-year anniversary in 2023 and accelerated our journey of innovation and expansion ...
The launch of Caresyntax CDaaS follows the recently announced addition of CQInsights (CQI) and appointment of Dr. Bruce Ramshaw as Chief Medical Informatics Officer (CMIO) for Caresyntax. The integration of the CQI solution into the Caresyntax platform enables a stack of technologies and capabilities with new digital workflows that can acquire curated data and ...
Synaptive Medical, a global medical device and technology company solving surgical, imaging and data challenges, is pleased to announce the appointment of Timothy J. Scannell as the new Chair of the Board of Directors, effective June 20, 2023. Mr. Scannell joined Synaptive Medical’s Board of Directors in August 2022, bringing a wealth of experience and expertise in the medical device ...
Ingredients for muscle mass and post-workout recovery remain mainstays in sports nutrition, but the category is evolving and broadening. Ingredient examples are phospholipids for cognition and probiotic cultures for digestive health. “It’s very well-known that health is increasingly perceived holistically by consumers, especially younger demographics,” said Paige Wilkinson, ...
JUNE Medical is delighted to announce a new agreement with a major US hospital group to supply the award-winning Galaxy II® self-retaining surgical retractors to over 1,600 hospitals in the US, commencing April 15, 2023. This game-changing device radically improves the safety and ease of surgical retraction for both patients and medical staff; its ergonomic design transforms the way in which ...
“Even when blood glucose levels and blood pressure are well-controlled, the risk of kidney disease progression and cardiovascular events remains high in patients with chronic kidney disease and type 2 diabetes,” said Dr. Michael Devoy, Chief Medical Officer of Bayer’s Pharmaceuticals Division. “Kerendia addresses a key cause of disease ...
ByBayer AG
Cummings joins the ONY Biotech team as Chief Medical Officer, and the founder of the company and former Chief Medical Officer, Dr. ...
Funding from the Series B will allow Oligomerix to accelerate its transition into Phase 1 human clinical development planned for early 3Q 2022. Oligomerix closes Series B extension to accelerate transition into Phase 1 human clinical development. “There is a significant need in the field of neurodegenerative diseases for novel treatment strategies, ...
” “These exciting results provides further confidence in the Oligomerix approach as we prepare to enter clinical testing next year,” said Bill Erhardt, M.D., Chief Medical Officer of Oligomerix. “By year end, Oligomerix will complete all necessary IND enabling studies and we will submit our IND to FDA during 1Q22. ...
Daly and Yatin Mundkur of Artiman Ventures, a Cellworks investor serving as Chief Technology Officer and Board Director, together lead the Cellworks Platform development strategy and model validation efforts. Other additions to the Cellworks leadership team include: Dr. Michael Castro as Chief Medical Officer; Brian Battey as ...
Utilizing the growing medical technologies to help prevent further bone mass loss can make the management of osteoporosis a little easier. ...
ATG-037, is an innovative asset in-licensed from Calithera with global rights and developed in-house by Antengene, has been approved to enter clinical studies in Australia and China, thus becoming the first oral small molecule CD73 inhibitor entering the clinical-stage in China and the wider Asia Pacific region. ...
Walid Abi-Saab has decided to retire from the company as Chief Medical Officer and member of the Executive Committee, effective 31 December 2022. ...
Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with Gastro Health, a national leading medical group specializing in digestive and liver health, to bring its AI Recruitment (AIR) technology to Gastro Health’s practices. ...
Michael Castro, MD, Neuro-oncologist, Medical Oncologist at Beverly Hills Cancer Center; Chief Medical Officer at Cellworks, Group Inc. and Co-Principal Investigator of the study. ...
Starton Therapeutics Inc., (the “Company”) a clinical stage biotechnology company announced today results from a 28-day efficacy study of STAR-LLD continuous subcutaneous (SC) infusion versus intraperitoneal (IP) lenalidomide in immunomodulatory drug (IMiD)-resistant RPMI CB.17 SCID mice. In this preclinical study: continuous delivery of lenalidomide resulted in improvements in the ...
Having clarified the Phase 3 study designs, the Company is now expanding its partnering activities on XF-73 Nasal with the aim of securing a deal in 2023. Dr Yuri Martina, Chief Medical Officer of Destiny Pharma, said: “Having finalized our Phase 3 strategy for our primary indication of SSI prevention, we are ready for the next steps in executing our ...